Expand and Invest to Grow

We have taken significant strides to expand our operating space through the acquisitions of Abide and Alder in 2019, which gave us the platforms needed to expand our areas of focus in neuroscience. With the 2020 launch of our newest treatment, for migraine,  in the U.S. and the global roll-out which was initiated in 2021, we are beginning to establish a new frontier in migraine prevention and expanding our presence into protein-based therapies. Furthermore, we are continuously expanding our existing portfolio of medicine into new markets.

The changes we made to how we approach R&D enables us to de-risk our internal pipeline compounds in early development. We utilize an experimental medicine approach to identify the effects of a drug in carefully selected patient populations, to find the most efficient clinical pathway powered by biomarkers and study designs and advance the most promising drug candidates into full development. 

We have made choices on where we will focus our efforts to enhance our operations and R&D. Also, we have taken steps to fortify our winning culture with increased agility, collaboration, diversity and inclusion. These are just a few of the many actions that are helping us deliver on the promise of our strategy to yield sustainable, long-term profitable growth. 

Our goal continues to be providing innovative treatments for patients that create value for Lundbeck. Achieving our fullest potential as a mid-size, highly specialized pharmaceutical company requires that we thoughtfully concentrate our efforts where we can make the most difference for patients. 

While we maximize the medicines and brands that we already have, we simultaneously focus on growing our pipeline with treatments for brain diseases for which there are few, if any, treatment options. We operate within niche diseases affecting subpopulations of people where there is a high, unmet medical need. By focusing on niche and rare disease neurology and psychiatry indications, we can best take advantage of our size and strong relationships with specialist healthcare providers to deliver powerful solutions to challenging diseases. 

Just as important to growing our pipeline and selling our medicines, is the manufacturing of our medicines, whether internally or via external contract manufacturing. We have strong internal capabilities within small and large molecules to support our R&D pipeline, including monoclonal antibody design, process and formulation development capabilities, as well as end-to-end internal small molecule manufacturing facilities.

Our three priorities across Production, Development & Supply remain quality, reliability and cost. We have a robust track-record on all three parameters and ambitious goals to continuously improve performance with a strong focus on operational excellence and sustainable sourcing. 

We aim to build on what we have achieved and capitalize further on the strong fundamentals that are deeply ingrained in Lundbeck; our rich heritage of developing and producing life-changing treatments for patients, our deep scientific knowledge in psychiatry and neurology and our patient-centric mindset. We will focus on embracing new biologies and technologies, adjusting and learning as we forge ahead. 

In the future, we will work with even more agility and collaboration across geographies, simplifying our processes and accelerating our ability to test and learn for faster, higher-quality decision making. This will fully leverage our diverse talent, knowledge and skillsets so that we can pursue solving some of the biggest brain disease challenges with the greatest patient reward.  

There are five strategic imperatives at the core of Lundbeck’s strategy.

1. Maximizing performance of existing brands
2. Expanding our operating space
3. Rebuilding our pipeline
4. Maintaining focus on profitability
5. Enhancing our organizational agility and collaboration

Over the past two years, we have made strategic choices around where we put our efforts across our entire business. With the choices we made, we have lofty ambitions for what the future should look like when we succeed. 

We aim to be the leader in brain health, in the eyes of our patients. We know we are well on our way when:

• We have top quartile financial results in our peer group. By focusing on our patients and our products, top financial performance will follow.   
• We have a premier neuroscience pipeline filled with assets that will make a difference to our patients.  
• We have an established and focused commercial footprint around commercially attractive patient segments in niche and rare neurology and psychiatry. 
• We are best in class in terms of how we use digital technologies to improve patient outcomes.  
• We are a company leveraging diversity, where top talents within neuroscience aspire to work. 
• We continue to deliver sustainable growth in revenue and profitability. 
• And finally, we are on track to be carbon neutral before 2050. Giving back to society is equally as important as financial performance. 

The culmination of all this together is what will make us #1 in Brain Health, serving the people who need new medicines to help them conquer brain diseases. It will take every brain being fully “in the game” to achieve it. We continue to prioritize and act, year by year to stay on track.